Pazopanib
Pazopanib is the only multi-kinase inhibitor approved for soft-tissue sarcoma (excluding fat-derived tumours), used after chemotherapy fails.
PALETTE: PFS 4.6 vs 1.6 months vs placebo (HR 0.31) in non-adipocytic STS after anthracycline; no OS benefit. Approved April 2012. Also RCC. Novartis.
- Route
- Oral
- Schedule
- 800 mg once daily on an empty stomach
- Monitoring
- Liver enzymes (boxed warning), blood pressure, thyroid, QT, pneumothorax in sarcoma
- Medicare
- Part D (self-administered)
Oral, self-administered, so it is a Part D drug: covered through a stand-alone Part D plan or Medicare Advantage drug benefit, usually on the specialty tier with 25 to 33% coinsurance until the annual cap ($2,000 in 2025, $2,100 in 2026). Generic pazopanib is available.
- Commercial insurance
- covered on label
Multi-source generic on low-cost tiers; usually no prior authorisation. Cash prices without insurance are modest.
Sources: Medicare.gov: Drug coverage (Part D) · Medicare.gov: Costs for Medicare drug coverage (annual out-of-pocket cap). Not medical or financial advice; verify with your plan.
- Appraised for
- First-line advanced RCC
- NHS England
- Routinely funded for the appraised indication (or via managed access)
Sources: NICE TA215 · SMC advice: pazopanib. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2009 | Advanced renal cell carcinoma |
| US | 2012 | Advanced non-adipocytic soft-tissue sarcoma after chemotherapy |
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Hypertension | 41% | 7% |
| Fatigue | 65% | 13% |
| ALT elevation | — | 8% |
| Pneumothorax | 3% | — |
PALETTE. Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Pazopanib" OR ABSTRACT:"Pazopanib" OR TITLE:"Votrient" OR ABSTRACT:"Votrient") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Pazopanib, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductAxitinib
Shares The angiogenic switch & tumour vessels, Anti-angiogenic therapy, VEGF / VEGFR, Renal cell carcinoma.
- ProductTivozanib
Shares The angiogenic switch & tumour vessels, Anti-angiogenic therapy, VEGF / VEGFR, Renal cell carcinoma.
- ProductSunitinib
Shares KIT, The angiogenic switch & tumour vessels, Anti-angiogenic therapy, VEGF / VEGFR.
- ProductRegorafenib
Shares KIT, The angiogenic switch & tumour vessels, Anti-angiogenic therapy, VEGF / VEGFR.
- ProductNintedanib
Shares The angiogenic switch & tumour vessels, Anti-angiogenic therapy, VEGF / VEGFR, Small-molecule kinase inhibitors.
- ProductPexidartinib
Shares KIT, Sarcomas (soft tissue, bone, GIST), Small-molecule kinase inhibitors.
- TrialSELECT
Shares Anti-angiogenic therapy, VEGF / VEGFR, Small-molecule kinase inhibitors.
- TrialSANET-ep and SANET-p
Shares Anti-angiogenic therapy, VEGF / VEGFR.